Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Significant Decrease in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 356,900 shares, a decline of 18.6% from the December 31st total of 438,500 shares. Currently, 2.9% of the shares of the stock are sold short. Based on an average daily volume of 100,900 shares, the days-to-cover ratio is currently 3.5 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health at the end of the most recent quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Aspira Women’s Health in a research note on Sunday, January 12th. They issued a “hold” rating on the stock.

Aspira Women’s Health Price Performance

Shares of NASDAQ:AWH traded down $0.01 during midday trading on Thursday, hitting $0.40. The company had a trading volume of 24,014 shares, compared to its average volume of 74,911. Aspira Women’s Health has a twelve month low of $0.36 and a twelve month high of $5.62. The stock has a market cap of $6.70 million, a price-to-earnings ratio of -0.33 and a beta of 1.42. The business’s 50-day simple moving average is $0.68 and its 200-day simple moving average is $0.89.

Aspira Women’s Health Company Profile

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.